Boston Scientific Corp (BSX)vsEdwards Lifesciences Corp (EW)
BSX
Boston Scientific Corp
$47.75
-2.75%
HEALTHCARE · Cap: $63.87B
EW
Edwards Lifesciences Corp
$89.60
+0.88%
HEALTHCARE · Cap: $49.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 217% more annual revenue ($20.61B vs $6.51B). BSX leads profitability with a 17.3% profit margin vs 15.4%. BSX appears more attractively valued with a PEG of 0.54. BSX earns a higher WallStSmart Score of 76/100 (B+).
BSX
Strong Buy76
out of 100
Grade: B+
EW
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-23.2%
Fair Value
$37.36
Current Price
$47.75
$10.39 premium
Margin of Safety
+69.3%
Fair Value
$257.97
Current Price
$89.60
$168.37 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.8%
Areas to Watch
Distress zone — elevated risk
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : EW
The strongest argument for EW centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bear Case : BSX
The primary concerns for BSX are Altman Z-Score.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.2x leaves little room for execution misses.
Key Dynamics to Monitor
EW carries more volatility with a beta of 0.85 — expect wider price swings.
EW is growing revenue faster at 13.6% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BSX scores higher overall (76/100 vs 55/100), backed by strong 17.3% margins and 11.6% revenue growth. EW offers better value entry with a 69.3% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?